TY - JOUR
T1 - Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease
AU - Apátiga-Pérez, Ricardo
AU - Soto-Rojas, Luis O.
AU - Campa-Córdoba, B. Berenice
AU - Luna-Viramontes, Nabil Itzi
AU - Cuevas, Elvis
AU - Villanueva-Fierro, Ignacio
AU - Ontiveros-Torres, Miguel Angel
AU - Bravo-Muñoz, Marely
AU - Flores-Rodríguez, Paola
AU - Garcés-Ramirez, Linda
AU - de la Cruz, Fidel
AU - Montiel-Sosa, José Francisco
AU - Pacheco-Herrero, Mar
AU - Luna-Muñoz, José
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/1
Y1 - 2022/1
N2 - Alzheimer's disease (AD) is clinically characterized by a progressive loss of cognitive functions and short-term memory. AD patients present two distinctive neuropathological lesions: neuritic plaques and neurofibrillary tangles (NFTs), constituted of beta-amyloid peptide (Aβ) and phosphorylated and truncated tau proteins. Aβ deposits around cerebral blood vessels (cerebral amyloid angiopathy, CAA) is a major contributor to vascular dysfunction in AD. Vascular amyloid deposits could be early events in AD due to dysfunction in the neurovascular unit (NVU) and the blood–brain barrier (BBB), deterioration of the gliovascular unit, and/or decrease of cerebral blood flow (CBF). These pathological events can lead to decreased Aβ clearance, facilitate a neuroinflammatory environment as well as synaptic dysfunction and, finally, lead to neurodegeneration. Here, we review the histopathological AD hallmarks and discuss the two-hit vascular hypothesis of AD, emphasizing the role of neurovascular dysfunction as an early factor that favors vascular Aβ aggregation and neurodegeneration. Addtionally, we emphasize that pericyte degeneration is a key and early element in AD that can trigger amyloid vascular accumulation and NVU/BBB dysfunction. Further research is required to better understand the early pathophysiological mechanisms associated with NVU alteration and CAA to generate early biomarkers and timely treatments for AD.
AB - Alzheimer's disease (AD) is clinically characterized by a progressive loss of cognitive functions and short-term memory. AD patients present two distinctive neuropathological lesions: neuritic plaques and neurofibrillary tangles (NFTs), constituted of beta-amyloid peptide (Aβ) and phosphorylated and truncated tau proteins. Aβ deposits around cerebral blood vessels (cerebral amyloid angiopathy, CAA) is a major contributor to vascular dysfunction in AD. Vascular amyloid deposits could be early events in AD due to dysfunction in the neurovascular unit (NVU) and the blood–brain barrier (BBB), deterioration of the gliovascular unit, and/or decrease of cerebral blood flow (CBF). These pathological events can lead to decreased Aβ clearance, facilitate a neuroinflammatory environment as well as synaptic dysfunction and, finally, lead to neurodegeneration. Here, we review the histopathological AD hallmarks and discuss the two-hit vascular hypothesis of AD, emphasizing the role of neurovascular dysfunction as an early factor that favors vascular Aβ aggregation and neurodegeneration. Addtionally, we emphasize that pericyte degeneration is a key and early element in AD that can trigger amyloid vascular accumulation and NVU/BBB dysfunction. Further research is required to better understand the early pathophysiological mechanisms associated with NVU alteration and CAA to generate early biomarkers and timely treatments for AD.
KW - Alzheimer´s disease
KW - Cerebral amyloid angiopathy
KW - Neuroinflammation
KW - Neurovascular dysfunction
KW - Pericyte degeneration
UR - http://www.scopus.com/inward/record.url?scp=85112816993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112816993&partnerID=8YFLogxK
U2 - 10.1007/s11011-021-00814-4
DO - 10.1007/s11011-021-00814-4
M3 - Review article
C2 - 34406560
AN - SCOPUS:85112816993
SN - 0885-7490
VL - 37
SP - 39
EP - 50
JO - Metabolic brain disease
JF - Metabolic brain disease
IS - 1
ER -